Circulating tumor DNA laboratory processes and clinical applications in nasopharyngeal carcinoma
Circulating tumor DNA (ctDNA), a subset of cell-free DNA (cfDNA), originates from primary tumors and metastatic lesions in cancer patients, often carrying genomic variations identical to those of the primary tumor. ctDNA analysis via liquid biopsy has proven to be a valuable biomarker for early canc...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1520733/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849321595977334784 |
|---|---|
| author | Ziman Wu Ziman Wu Haiyan Yang Haiyan Yang Xinying Li Xiang Ji Chan Mo Zhou Zheng Yafei Xu Dan Xiong Dan Xiong Dan Xiong |
| author_facet | Ziman Wu Ziman Wu Haiyan Yang Haiyan Yang Xinying Li Xiang Ji Chan Mo Zhou Zheng Yafei Xu Dan Xiong Dan Xiong Dan Xiong |
| author_sort | Ziman Wu |
| collection | DOAJ |
| description | Circulating tumor DNA (ctDNA), a subset of cell-free DNA (cfDNA), originates from primary tumors and metastatic lesions in cancer patients, often carrying genomic variations identical to those of the primary tumor. ctDNA analysis via liquid biopsy has proven to be a valuable biomarker for early cancer detection, minimal residual disease (MRD) assessment, monitoring tumor recurrence, and evaluating treatment efficacy. However, despite advancements in ctDNA analysis technologies, standardized protocols for its extraction and detection have yet to be established. Each step of the process—from pre-analytical variables to detection techniques—significantly impacts the accuracy and reliability of ctDNA analysis. This review examines recent developments in ctDNA detection methods, focusing on pre-analytical factors such as specimen types, collection tubes, centrifugation protocols, and storage conditions, alongside high-throughput and ultra-sensitive detection technologies. It also briefly discusses the clinical potential of liquid biopsy in nasopharyngeal carcinoma (NPC). |
| format | Article |
| id | doaj-art-ff6f72948b0a443e88fb8e445166b0b2 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-ff6f72948b0a443e88fb8e445166b0b22025-08-20T03:49:42ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-05-011510.3389/fonc.2025.15207331520733Circulating tumor DNA laboratory processes and clinical applications in nasopharyngeal carcinomaZiman Wu0Ziman Wu1Haiyan Yang2Haiyan Yang3Xinying Li4Xiang Ji5Chan Mo6Zhou Zheng7Yafei Xu8Dan Xiong9Dan Xiong10Dan Xiong11School of Medical Technology, Xinxiang Medical University, Xinxiang, ChinaMedical Laboratory of the Third Affiliated Hospital of Shenzhen University, Shenzhen, ChinaMedical Laboratory of the Third Affiliated Hospital of Shenzhen University, Shenzhen, ChinaShantou University Medical College, Shantou, ChinaMedical Laboratory of the Third Affiliated Hospital of Shenzhen University, Shenzhen, ChinaMedical Laboratory of the Third Affiliated Hospital of Shenzhen University, Shenzhen, ChinaMedical Laboratory of the Third Affiliated Hospital of Shenzhen University, Shenzhen, ChinaMedical Laboratory of the Third Affiliated Hospital of Shenzhen University, Shenzhen, ChinaDepartment of Cell Biology and Genetics, Shenzhen University Health Science Center, Shenzhen, ChinaSchool of Medical Technology, Xinxiang Medical University, Xinxiang, ChinaMedical Laboratory of the Third Affiliated Hospital of Shenzhen University, Shenzhen, ChinaShantou University Medical College, Shantou, ChinaCirculating tumor DNA (ctDNA), a subset of cell-free DNA (cfDNA), originates from primary tumors and metastatic lesions in cancer patients, often carrying genomic variations identical to those of the primary tumor. ctDNA analysis via liquid biopsy has proven to be a valuable biomarker for early cancer detection, minimal residual disease (MRD) assessment, monitoring tumor recurrence, and evaluating treatment efficacy. However, despite advancements in ctDNA analysis technologies, standardized protocols for its extraction and detection have yet to be established. Each step of the process—from pre-analytical variables to detection techniques—significantly impacts the accuracy and reliability of ctDNA analysis. This review examines recent developments in ctDNA detection methods, focusing on pre-analytical factors such as specimen types, collection tubes, centrifugation protocols, and storage conditions, alongside high-throughput and ultra-sensitive detection technologies. It also briefly discusses the clinical potential of liquid biopsy in nasopharyngeal carcinoma (NPC).https://www.frontiersin.org/articles/10.3389/fonc.2025.1520733/fullCtDNApre-analyticaldetected methodsbiomarkernasopharyngeal carcinoma |
| spellingShingle | Ziman Wu Ziman Wu Haiyan Yang Haiyan Yang Xinying Li Xiang Ji Chan Mo Zhou Zheng Yafei Xu Dan Xiong Dan Xiong Dan Xiong Circulating tumor DNA laboratory processes and clinical applications in nasopharyngeal carcinoma Frontiers in Oncology CtDNA pre-analytical detected methods biomarker nasopharyngeal carcinoma |
| title | Circulating tumor DNA laboratory processes and clinical applications in nasopharyngeal carcinoma |
| title_full | Circulating tumor DNA laboratory processes and clinical applications in nasopharyngeal carcinoma |
| title_fullStr | Circulating tumor DNA laboratory processes and clinical applications in nasopharyngeal carcinoma |
| title_full_unstemmed | Circulating tumor DNA laboratory processes and clinical applications in nasopharyngeal carcinoma |
| title_short | Circulating tumor DNA laboratory processes and clinical applications in nasopharyngeal carcinoma |
| title_sort | circulating tumor dna laboratory processes and clinical applications in nasopharyngeal carcinoma |
| topic | CtDNA pre-analytical detected methods biomarker nasopharyngeal carcinoma |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1520733/full |
| work_keys_str_mv | AT zimanwu circulatingtumordnalaboratoryprocessesandclinicalapplicationsinnasopharyngealcarcinoma AT zimanwu circulatingtumordnalaboratoryprocessesandclinicalapplicationsinnasopharyngealcarcinoma AT haiyanyang circulatingtumordnalaboratoryprocessesandclinicalapplicationsinnasopharyngealcarcinoma AT haiyanyang circulatingtumordnalaboratoryprocessesandclinicalapplicationsinnasopharyngealcarcinoma AT xinyingli circulatingtumordnalaboratoryprocessesandclinicalapplicationsinnasopharyngealcarcinoma AT xiangji circulatingtumordnalaboratoryprocessesandclinicalapplicationsinnasopharyngealcarcinoma AT chanmo circulatingtumordnalaboratoryprocessesandclinicalapplicationsinnasopharyngealcarcinoma AT zhouzheng circulatingtumordnalaboratoryprocessesandclinicalapplicationsinnasopharyngealcarcinoma AT yafeixu circulatingtumordnalaboratoryprocessesandclinicalapplicationsinnasopharyngealcarcinoma AT danxiong circulatingtumordnalaboratoryprocessesandclinicalapplicationsinnasopharyngealcarcinoma AT danxiong circulatingtumordnalaboratoryprocessesandclinicalapplicationsinnasopharyngealcarcinoma AT danxiong circulatingtumordnalaboratoryprocessesandclinicalapplicationsinnasopharyngealcarcinoma |